Sold as Glycophos. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Sodium Glycerophosphate (sold as Glycophos), first approved Jul 29, 2026, with 0 new uses approved and 0 published complete response letters.
| Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator WeaningMechanical Ventilation, Weaning Failure · Peking Union Medical College | — | Recruiting | Jan 1, 2025 |
| Efficacy of Diet on Quality of Life in Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting · Terry L. Wahls | Not applicable | Active, not recruiting | Aug 16, 2021 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 29, 2026 | GlycophosNDA 220381 · New active ingredient | Fresenius Kabi USA | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA